BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hellenbart EL, Faulkenberg KD, Finks SW. Evaluation of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag 2017;13:325-42. [PMID: 28860793 DOI: 10.2147/VHRM.S121661] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Al-Horani RA. Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections. Am J Cardiovasc Drugs 2020;20:525-33. [PMID: 32918208 DOI: 10.1007/s40256-020-00438-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Fry E, Bollempali H, Suarez K, Banchs J, Michel J. Watchman outcomes comparing post-implantation anticoagulation with warfarin versus direct oral anticoagulants. J Interv Card Electrophysiol 2021;61:137-44. [PMID: 32504227 DOI: 10.1007/s10840-020-00790-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Kampouraki E, Abohelaika S, Avery P, Biss T, Murphy P, Wynne H, Kamali F. Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing. J Thromb Thrombolysis 2021;52:170-8. [PMID: 33131001 DOI: 10.1007/s11239-020-02326-x] [Reference Citation Analysis]
4 AlAmmari M, Sultana K, Alturaiki A, Thomas A, AlBabtain M, AlAyoubi F, Richi H. The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population. PLoS One 2021;16:e0250502. [PMID: 33939729 DOI: 10.1371/journal.pone.0250502] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Crawley RM, Anderson RL. Prevention and Treatment of Bleeding with Direct Oral Anticoagulants. Drugs 2020;80:1293-308. [PMID: 32691292 DOI: 10.1007/s40265-020-01345-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Bröcker A, Tarenz C, Suzart-Woischnik K. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert Opin Drug Saf 2021;:1-12. [PMID: 34806928 DOI: 10.1080/14740338.2022.1998451] [Reference Citation Analysis]
7 Gupta K, Khan A, Kumar M, Sawalha K, Abozenah M, Singhania R. Readmissions Rates After Myocardial Infarction for Gastrointestinal Bleeding: A National Perspective. Dig Dis Sci 2021;66:751-9. [PMID: 32436123 DOI: 10.1007/s10620-020-06315-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Patil T, Murphy K, Woodard L, Lebrecht M. Proton Pump Inhibitor Utilization in Veteran Patients on Combined Antithrombotic Therapy and Validation of Simplified Bleeding Risk Score. Pharmacotherapy 2020;40:1219-27. [PMID: 33073362 DOI: 10.1002/phar.2477] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ojetti V, Saviano A, Brigida M, Saviano L, Migneco A, Franceschi F. A Review on the Use of Reversal Agents of Direct Oral Anticogulant Drugs in Case of Gastrointestinal Bleeding. Rev Recent Clin Trials 2020;15:309-20. [PMID: 32579506 DOI: 10.2174/1574887115666200624193938] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Rahmanzade R, Cabrera Diaz F, Zaugg C, Schuetz P, Salili AR. Therapeutic duplication of anticoagulants: a retrospective study of frequency and consequences in a tertiary referral hospital. Thromb J 2020;18:14. [PMID: 32774174 DOI: 10.1186/s12959-020-00227-w] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Mujer MTP, Rai MP, Atti V, Dimaandal IL, Chan AS, Shrotriya S, Gundabolu K, Dhakal P. An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants. Adv Hematol 2020;2020:7636104. [PMID: 32231703 DOI: 10.1155/2020/7636104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Roşian AN, Iancu M, Trifa AP, Roşian ŞH, Mada C, Gocan CP, Niţă T, Istratoaie S, Boarescu PM, Buzoianu AD. An Exploratory Association Analysis of ABCB1 rs1045642 and ABCB1 rs4148738 with Non-Major Bleeding Risk in Atrial Fibrillation Patients Treated with Dabigatran or Apixaban. J Pers Med 2020;10:E133. [PMID: 32961964 DOI: 10.3390/jpm10030133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Roşian AN, Roşian ŞH, Kiss B, Ştefan MG, Trifa AP, Ober CD, Anchidin O, Buzoianu AD. Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients. Genes (Basel) 2020;11:E438. [PMID: 32316515 DOI: 10.3390/genes11040438] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Falconer N, Barras M, Abdel-Hafiz A, Radburn S, Cottrell N. Evaluation of two European risk models for predicting medication harm in an Australian patient cohort. Eur J Clin Pharmacol 2022. [PMID: 35041044 DOI: 10.1007/s00228-021-03271-1] [Reference Citation Analysis]
15 Trujillo Agudelo D, Ramirez Quintero JD, Arango Barrientos M. Successful treatment of heparin-induced thrombocytopenia with apixaban in a patient with chronic kidney disease requiring hemodialysis. Clin Case Rep 2018;6:2147-9. [PMID: 30455909 DOI: 10.1002/ccr3.1817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Panchal H, Agashe A, Sancheti PK, Kulkarni NB, Taur SR. Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study. SAGE Open Med 2021;9:20503121211049962. [PMID: 34659763 DOI: 10.1177/20503121211049962] [Reference Citation Analysis]
17 Sun M, Miyazawa K, Pendekanti T, Razmi A, Firlar E, Yang S, Shokuhfar T, Li O, Li W, Sen Gupta A. Combination targeting of 'platelets + fibrin' enhances clot anchorage efficiency of nanoparticles for vascular drug delivery. Nanoscale 2020;12:21255-70. [PMID: 33063812 DOI: 10.1039/d0nr03633a] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Riddle M, McCallum R, Ojha CP, Paul TK, Gupta V, Baran DA, Prakash BV, Misra A, Mares AC, Abedin M, Kedar A, Mulukutla V, Ibrahim A, Nagarajarao H. Advances in the management of atrial fibrillation with a special focus on non-pharmacological approaches to prevent thromboembolism: a review of current recommendations. J Investig Med 2020;68:1317-33. [PMID: 33203786 DOI: 10.1136/jim-2020-001500] [Reference Citation Analysis]
19 Barr D, Epps QJ. Direct oral anticoagulants: a review of common medication errors. J Thromb Thrombolysis 2019;47:146-54. [PMID: 30298305 DOI: 10.1007/s11239-018-1752-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
20 Bass ME, Kiser TH, Page RL 2nd, McIlvennan CK, Allen LA, Wright G, Shakowski C. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Thromb Thrombolysis 2021. [PMID: 33420896 DOI: 10.1007/s11239-020-02371-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
21 Chua CXK, Tan JHI, Bin Abd Razak HR. Enoxaparin Versus Direct Oral Anticoagulants for Venous Thromboembolism in Asians Undergoing Total Knee Arthroplasty: A Meta-Analysis and Systematic Review. J Arthroplasty 2021:S0883-5403(21)00895-0. [PMID: 34843908 DOI: 10.1016/j.arth.2021.11.030] [Reference Citation Analysis]
22 Kolonics-Farkas AM, Šterclová M, Mogulkoc N, Kus J, Hájková M, Müller V, Jovanovic D, Tekavec-Trkanjec J, Littnerová S, Hejduk K, Vašáková M. Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE. Drug Saf 2020;43:971-80. [PMID: 32734423 DOI: 10.1007/s40264-020-00978-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
23 Netley J, Howard K, Wilson W. Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review. J Thromb Thrombolysis 2019;48:359-65. [PMID: 30963393 DOI: 10.1007/s11239-019-01857-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
24 Qazi JZ, Schnitzer ME, Côté R, Martel MJ, Dorais M, Perreault S. Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge. PLoS One 2021;16:e0246691. [PMID: 33657116 DOI: 10.1371/journal.pone.0246691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Al-Horani RA, Abdelfadiel EI, Afosah DK, Morla S, Sistla JC, Mohammed B, Martin EJ, Sakagami M, Brophy DF, Desai UR. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding. J Thromb Haemost 2019;17:2110-22. [PMID: 31397071 DOI: 10.1111/jth.14606] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
26 Carman TL. Oral anticoagulation and health care utilization in venous thromboembolism: What can we do to do better? Vasc Med 2020;25:557-8. [PMID: 32821016 DOI: 10.1177/1358863X20945369] [Reference Citation Analysis]